Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.2 Million | -28.01 Million | -26.64 Million | -27.66 Million | -28.2 Million | -27.24 Million |
| Net Income | -8.44 Million | -40.93 Million | -26.51 Million | -17.2 Million | -28.63 Million | -37.42 Million |
| Depreciation & Amortization | 794 Thousand | 1.44 Million | 1.52 Million | 1.83 Million | 1.78 Million | 1.11 Million |
| Deferred income taxes | - | - | -531 Thousand | 1.04 Million | 85 Thousand | - |
| Stock-based compensation | 935 Thousand | 1.62 Million | 2.17 Million | 2.78 Million | 2.77 Million | 3.59 Million |
| Change in working capital | -1.2 Million | -4.01 Million | 1.4 Million | -2.87 Million | -609 Thousand | 481 Thousand |
| Other non-cash items | -7.27 Million | 13.87 Million | -4.69 Million | -13.25 Million | -3.6 Million | 4.98 Million |
| Investing Cash Flow | 407 Thousand | 7.2 Million | -126 Thousand | 157 Thousand | 8.98 Million | 607 Thousand |
| Investments in PPE | -899 Thousand | -123 Thousand | -393 Thousand | -319 Thousand | -622 Thousand | -1.76 Million |
| Acquisitions | 1.34 Million | 6 Million | - | 235 Thousand | - | 932 Thousand |
| Investment purchases | - | - | - | -476 Thousand | - | -26.56 Million |
| Sales/Maturities of investments | - | 1.09 Million | - | 241 Thousand | 9.37 Million | 28.85 Million |
| Other Investing Activities | 1.3 Million | 235 Thousand | 267 Thousand | 476 Thousand | 230 Thousand | -858 Thousand |
| Financing Cash Flow | 9.35 Million | 3.24 Million | 39.52 Million | 5.39 Million | 18.27 Million | 43.92 Million |
| Debt repayment | -145 Thousand | -896 Thousand | -1.13 Million | -1.44 Million | -1.48 Million | -749 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -124 Thousand | - | - | - | - |
| Common Stock Issuance | 9.49 Million | - | 36.56 Million | - | 16.44 Million | 43.01 Million |
| Other Financing Activities | 9.5 Million | 4.26 Million | 4.08 Million | 6.84 Million | 3.31 Million | 1.66 Million |
| Accounts receivables | -1.2 Million | 306 Thousand | - | - | -1.77 Million | -1.45 Million |
| Accounts payables | - | -4.32 Million | 2.96 Million | -1.72 Million | 1.16 Million | 1.94 Million |
| Inventory | - | - | - | - | 1.77 Million | -481 Thousand |
| Other working capital | -6.49 Million | 306 Thousand | -1.55 Million | -1.14 Million | -1.77 Million | -1.45 Million |
| Cash at beginning of period | 12.44 Million | 30.01 Million | 17.23 Million | 39.33 Million | 40.54 Million | 23.25 Million |
| Cash at end of period | 7 Million | 12.44 Million | 30.01 Million | 17.23 Million | 39.33 Million | 40.54 Million |
| Capital Expenditure | -899 Thousand | -123 Thousand | -393 Thousand | -319 Thousand | -622 Thousand | -1.76 Million |
| Effect of forex changes on cash | -1000.00 | -6000.00 | 32 Thousand | 8000.00 | -265 Thousand | 3000.00 |
| Net cash flow / Change in cash | -5.44 Million | -17.57 Million | 12.78 Million | -22.1 Million | -1.2 Million | 17.28 Million |
| Free Cash Flow | -16.1 Million | -28.13 Million | -27.03 Million | -27.98 Million | -28.82 Million | -29.01 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.04 Million | -4.7 Million | -8.44 Million | -3.74 Million | -40.93 Million | -26.87 Million |
| Depreciation & Amortization | 229 Thousand | 397 Thousand | 794 Thousand | 397 Thousand | 1.44 Million | 469 Thousand |
| Deferred income taxes | - | - | - | -1.23 Million | - | -1.48 Million |
| Stock-based compensation | 6000.00 | 491 Thousand | 935 Thousand | 444 Thousand | 1.62 Million | 548 Thousand |
| Change in working capital | 306 Thousand | 2.39 Million | -6.49 Million | -3.59 Million | -4.01 Million | -2.16 Million |
| Other non-cash items | -328 Thousand | -5.44 Million | 538 Thousand | -594.99 Thousand | 13.87 Million | 17.81 Million |
| Investing Cash Flow | -118 Thousand | -558 Thousand | 407 Thousand | 965 Thousand | 7.2 Million | 6.06 Million |
| Investments in PPE | - | -583 Thousand | -934 Thousand | -350 Thousand | -123 Thousand | -17 Thousand |
| Acquisitions | - | 26 Thousand | 1.34 Million | 1.31 Million | 6 Million | 6 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | 1.09 Million | - |
| Other Investing Activities | -118 Thousand | 25 Thousand | 1.3 Million | 1.28 Million | 235 Thousand | 79 Thousand |
| Financing Cash Flow | 2.17 Million | 9.45 Million | 9.35 Million | -102 Thousand | 3.24 Million | 3.68 Million |
| Debt repayment | -83 Thousand | - | -145 Thousand | -92 Thousand | -896 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 10 Thousand | - | -10 Thousand | -124 Thousand | 1000.00 |
| Common Stock Issuance | - | 9.49 Million | 9.49 Million | - | - | - |
| Other Financing Activities | 2.25 Million | 9.45 Million | 10 Thousand | -10 Thousand | 4.26 Million | 4.08 Million |
| Accounts receivables | 306 Thousand | -1.2 Million | -1.2 Million | - | 306 Thousand | 306 Thousand |
| Accounts payables | - | - | - | - | -4.32 Million | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | 3.59 Million | -6.49 Million | -3.59 Million | 306 Thousand | -2.16 Million |
| Cash at beginning of period | 7 Million | 4.97 Million | 12.44 Million | 12.44 Million | 30.01 Million | 14.38 Million |
| Cash at end of period | 6.22 Million | 7 Million | 7 Million | 4.97 Million | 12.44 Million | 12.44 Million |
| Capital Expenditure | - | -583 Thousand | -934 Thousand | -350 Thousand | -123 Thousand | -17 Thousand |
| Effect of forex changes on cash | - | - | -1000.00 | -1000.00 | -6000.00 | 14 Thousand |
| Net cash flow / Change in cash | -774 Thousand | 2.02 Million | -5.44 Million | -7.46 Million | -17.57 Million | -1.94 Million |
| Free Cash Flow | -2.83 Million | -7.45 Million | -16.13 Million | -8.68 Million | -28.13 Million | -11.71 Million |
300008
SITC-PA
TANFACIND
BDCM
FBGI
VILN